These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29548345)

  • 1. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis.
    Palmer M; Jennings L; Silberg DG; Bliss C; Martin P
    BMC Pharmacol Toxicol; 2018 Mar; 19(1):10. PubMed ID: 29548345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial.
    Tiessen RG; Kennedy CA; Keller BT; Levin N; Acevedo L; Gedulin B; van Vliet AA; Dorenbaum A; Palmer M
    BMC Gastroenterol; 2018 Jan; 18(1):3. PubMed ID: 29304731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
    J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorption, Distribution, Metabolism, and Excretion of [
    Siebers N; Palmer M; Silberg DG; Jennings L; Bliss C; Martin PT
    Eur J Drug Metab Pharmacokinet; 2018 Feb; 43(1):91-101. PubMed ID: 28702877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.
    Salic K; Kleemann R; Wilkins-Port C; McNulty J; Verschuren L; Palmer M
    PLoS One; 2019; 14(6):e0218459. PubMed ID: 31233523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation.
    Graffner H; Gillberg PG; Rikner L; Marschall HU
    Aliment Pharmacol Ther; 2016 Jan; 43(2):303-10. PubMed ID: 26527417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Sanyal A; Charles ED; Neuschwander-Tetri BA; Loomba R; Harrison SA; Abdelmalek MF; Lawitz EJ; Halegoua-DeMarzio D; Kundu S; Noviello S; Luo Y; Christian R
    Lancet; 2019 Dec; 392(10165):2705-2717. PubMed ID: 30554783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
    Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
    Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial.
    Kumagai Y; Amano H; Sasaki Y; Nakagawa C; Maeda M; Oikawa I; Furuie H
    Br J Clin Pharmacol; 2018 Oct; 84(10):2393-2404. PubMed ID: 29959787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
    Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
    JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
    Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
    BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers.
    Younis IR; Kirby BJ; Billin AN; Xiao D; Song Q; Watkins TR; Othman AA
    Clin Transl Sci; 2023 Mar; 16(3):536-547. PubMed ID: 36573450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are overweight or obese: a randomized, double-blind, placebo-controlled, multiple-dose phase 1b study.
    Lin D; Xiao H; Yang K; Li J; Ye S; Liu Y; Jing S; Lin Y; Yang Y; Huang L; Yuan J; Li Z; Yang J; Gao H; Xie Y; Xu M; Yan L
    BMC Med; 2024 May; 22(1):209. PubMed ID: 38807146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: The ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation--a double-blind study.
    Simrén M; Bajor A; Gillberg PG; Rudling M; Abrahamsson H
    Aliment Pharmacol Ther; 2011 Jul; 34(1):41-50. PubMed ID: 21545606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
    Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
    Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
    Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
    JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.
    Xu J; Zhang H; Chen H; Zhu X; Jia H; Xu Z; Huo D; Zhang H; Li C; Ding Y
    Ann Med; 2023; 55(2):2264850. PubMed ID: 38071661
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea.
    Camilleri M; Nord SL; Burton D; Oduyebo I; Zhang Y; Chen J; Im K; Bhad P; Badman MK; Sanders DS; Walters JRF
    Aliment Pharmacol Ther; 2020 Sep; 52(5):808-820. PubMed ID: 32702169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.